
    
      The anti-PD-1 drug camrelizumab combined with apatinib mesylate was used to treat relapsed
      platinum-resistant epithelial ovarian cancer, and the effectiveness and safety of the
      treatment plan was evaluated by objective remission rate, progression-free survival, and
      major safety indicators , so as to provide patients a more beneficial treatment plan.
    
  